

Celia C Labranche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5579935/publications.pdf>

Version: 2024-02-01

158
papers

11,013
citations

66234

42
h-index

39575

94
g-index

173
all docs

173
docs citations

173
times ranked

15390
citing authors

#	ARTICLE	IF	CITATIONS
1	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. <i>Journal of Virology</i> , 2022, 96, JVI0155221.	1.5	13
2	E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. <i>Vaccines</i> , 2022, 10, 295.	2.1	2
3	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 27.	2.9	13
4	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. <i>Cell Reports</i> , 2022, 38, 110436.	2.9	6
5	Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2022, 225, 1731-1740.	1.9	5
6	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2
7	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. <i>Journal of Virology</i> , 2022, 96, e0023122.	1.5	2
8	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 23-31.e4.	5.1	308
9	Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. <i>Journal of Controlled Release</i> , 2021, 330, 529-539.	4.8	31
10	The high-affinity immunoglobulin receptor Fc γ RI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16
11	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. <i>Npj Vaccines</i> , 2021, 6, 24.	2.9	33
12	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <i>Journal of Immunology</i> , 2021, 206, 1266-1283.	0.4	8
13	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	1.9	16
14	The Immunological Impact of Adenovirus Early Genes on Vaccine-Induced Responses in Mice and Nonhuman Primates. <i>Journal of Virology</i> , 2021, 95, .	1.5	1
15	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	13.5	57
16	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	2.1	2
17	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53
18	A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. <i>Journal of Virology</i> , 2021, 95, e0235020.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. <i>Vaccines</i> , 2021, 9, 774.	2.1	5
20	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009736.	2.1	18
21	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. <i>Nature Communications</i> , 2021, 12, 4817.	5.8	35
22	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 670561.	2.2	3
23	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. <i>Journal of Immunological Methods</i> , 2020, 479, 112736.	0.6	9
24	An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice. <i>Annals of Biomedical Engineering</i> , 2020, 48, 1991-2001.	1.3	13
25	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. <i>Journal of Virology</i> , 2020, 94, .	1.5	11
26	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 95, .	1.5	5
27	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	2.9	11
28	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2020, 16, e1008753.	2.1	61
29	An Efficient Microwave-Mediated Synthesis of Hexavalent Sialic Acid Sulfoglycodendrimers as Potential Anti-HIV Agents. <i>ACS Applied Polymer Materials</i> , 2020, 2, 4345-4351.	2.0	1
30	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
31	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , 2020, 5, 36.	2.9	12
32	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. <i>Nature Medicine</i> , 2020, 26, 932-940.	15.2	124
33	Impact of T _H 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	30
34	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
35	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. <i>MBio</i> , 2020, 11, .	1.8	25
36	CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses. <i>Vaccines</i> , 2020, 8, 284.	2.1	7

#	ARTICLE	IF	CITATIONS
37	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. <i>Science Immunology</i> , 2020, 5, .	5.6	90
38	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	2.1	14
39	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> , 2020, 182, 812-827.e19.	13.5	3,551
40	The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans. <i>ACS Chemical Biology</i> , 2020, 15, 789-798.	1.6	9
41	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. <i>Journal of Virology</i> , 2020, 94, .	1.5	29
42	Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help. <i>Nature Communications</i> , 2020, 11, 2550.	5.8	17
43	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020, 130, 5157-5170.	3.9	22
44	SIV infection duration largely determines broadening of neutralizing antibody response in macaques. <i>Journal of Clinical Investigation</i> , 2020, 130, 5413-5424.	3.9	2
45	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
46	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
47	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
48	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
49	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. <i>Journal of Virology</i> , 2019, 93, .	1.5	12
50	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 148-160.	1.8	4
51	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
52	Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. <i>Immunity</i> , 2019, 51, 724-734.e4.	6.6	13
53	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. <i>Nature Communications</i> , 2019, 10, 4272.	5.8	149
54	Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection. <i>Molecular Systems Biology</i> , 2019, 15, e8747.	3.2	17

#	ARTICLE	IF	CITATIONS
55	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019, 10, 2355.	5.8	116
56	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
57	Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. <i>Lancet HIV</i> , 2019, 6, e230-e239.	2.1	84
58	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	37
59	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 15, 36-47.	2.3	79
60	Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities. <i>ACS Central Science</i> , 2019, 5, 237-249.	5.3	33
61	HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. <i>Nature Communications</i> , 2019, 10, 798.	5.8	61
62	Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. <i>PLoS ONE</i> , 2019, 14, e0212649.	1.1	12
63	Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. <i>Journal of Virology</i> , 2019, 93, .	1.5	12
64	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. <i>Cell Reports</i> , 2019, 29, 3060-3072.e7.	2.9	26
65	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	2.1	19
66	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. <i>Journal of Virology</i> , 2019, 93, .	1.5	66
67	Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. <i>JCI Insight</i> , 2019, 4, .	2.3	50
68	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	30
69	Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. <i>Journal of Virology</i> , 2018, 92, .	1.5	66
70	Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. <i>Virology</i> , 2018, 514, 106-117.	1.1	29
71	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2018, 293, 1688-1701.	1.6	40
72	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. <i>Journal of Virology</i> , 2018, 92, .	1.5	24

#	ARTICLE	IF	CITATIONS
73	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	2.0	26
74	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , 2018, 13, e0194266.	1.1	14
75	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007431.	2.1	36
76	Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 <i>N</i> -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10116-10125.	2.9	21
77	Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 867-878.	0.5	8
78	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986.	2.1	28
79	Control of Heterologous Simian Immunodeficiency Virus SIV <i>smE660</i> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
80	Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying <i>env</i> from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. <i>Journal of Virology</i> , 2018, 92, .	1.5	3
81	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	4.2	366
82	Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine. <i>ACS Central Science</i> , 2018, 4, 582-589.	5.3	34
83	Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. <i>PLoS Pathogens</i> , 2018, 14, e1006944.	2.1	29
84	Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. <i>Mucosal Immunology</i> , 2018, 11, 1716-1726.	2.7	15
85	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. <i>PLoS Pathogens</i> , 2018, 14, e1006913.	2.1	111
86	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	29
87	An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. <i>Vaccine Journal</i> , 2017, 24, .	3.2	8
88	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
89	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
90	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. <i>Journal of Virology</i> , 2017, 91, .	1.5	57

#	ARTICLE	IF	CITATIONS
91	Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses. <i>Cell Chemical Biology</i> , 2017, 24, 1513-1522.e4.	2.5	38
92	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
93	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. <i>Cell Reports</i> , 2017, 20, 1805-1817.	2.9	171
94	Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. <i>Journal of Virology</i> , 2017, 91, .	1.5	14
95	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
96	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	45
97	Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2017, 292, 278-291.	1.6	18
98	Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. <i>Viruses</i> , 2017, 9, 135.	1.5	3
99	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006572.	2.1	28
100	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. <i>PLoS ONE</i> , 2017, 12, e0181886.	1.1	16
101	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	3.7	41
102	Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4446-4451.	3.3	20
103	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. <i>Journal of Immunology</i> , 2016, 196, 3064-3078.	0.4	56
104	High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5 α -Restrictive Macaques. <i>Journal of Immunology</i> , 2016, 197, 3586-3596.	0.4	16
105	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	1.5	13
106	Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2016, 90, 8842-8854.	1.5	34
107	Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. <i>Vaccine</i> , 2016, 34, 5886-5894.	1.7	19
108	Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. <i>Virology Journal</i> , 2016, 13, 200.	1.4	11

#	ARTICLE	IF	CITATIONS
109	Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw034.	0.4	15
110	Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1. <i>MSphere</i> , 2016, 1, .	1.3	5
111	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
112	Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2016, 90, 4966-4980.	1.5	9
113	Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques. <i>PLoS ONE</i> , 2016, 11, e0152760.	1.1	11
114	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. <i>PLoS ONE</i> , 2016, 11, e0153484.	1.1	20
115	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. <i>PLoS ONE</i> , 2016, 11, e0157391.	1.1	33
116	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. <i>PLoS Pathogens</i> , 2016, 12, e1005864.	2.1	138
117	Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. <i>Retrovirology</i> , 2015, 12, 82.	0.9	156
118	DNA Vaccine Molecular Adjuvants SP-D-BAFF and SP-D-APRIL Enhance Anti-gp120 Immune Response and Increase HIV-1 Neutralizing Antibody Titers. <i>Journal of Virology</i> , 2015, 89, 4158-4169.	1.5	51
119	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. <i>Cell</i> , 2015, 163, 1702-1715.	13.5	341
120	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E992-9.	3.3	117
121	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015, 11, e1004932.	2.1	141
122	HIV-1 neutralizing antibodies induced by native-like envelope trimers. <i>Science</i> , 2015, 349, aac4223.	6.0	482
123	Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in <i>Macaca nemestrina</i> Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. <i>Journal of Virology</i> , 2015, 89, 10156-10175.	1.5	19
124	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection. <i>Journal of Virology</i> , 2015, 89, 4690-4695.	1.5	31
125	An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 9154-9166.	1.5	14
126	Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5 ⁺ and CXCR5 ^{hi} CD4 T Cell Responses in Rhesus Macaques. <i>Journal of Immunology</i> , 2015, 195, 994-1005.	0.4	50

#	ARTICLE	IF	CITATIONS
127	Antigenicity and Immunogenicity of a Trimeric Envelope Protein from an Indian Clade C HIV-1 Isolate. <i>Journal of Biological Chemistry</i> , 2015, 290, 9195-9208.	1.6	11
128	A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1126-1138.	0.5	8
129	Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 887-887.	1.5	0
130	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	1.5	35
131	Phenotypic Correlates of HIV-1 Macrophage Tropism. <i>Journal of Virology</i> , 2015, 89, 11294-11311.	1.5	54
132	Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. <i>Journal of Virology</i> , 2015, 89, 10707-10711.	1.5	2
133	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. <i>Journal of Infectious Diseases</i> , 2015, 211, 947-955.	1.9	140
134	Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques. <i>PLoS ONE</i> , 2015, 10, e0120451.	1.1	29
135	Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. <i>PLoS ONE</i> , 2015, 10, e0128823.	1.1	9
136	Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. <i>PLoS Pathogens</i> , 2015, 11, e1005101.	2.1	59
137	DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques. <i>PLoS ONE</i> , 2014, 9, e91550.	1.1	42
138	Immunization of Rabbits with Highly Purified, Soluble, Trimeric Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces a Vigorous B Cell Response and Broadly Cross-Reactive Neutralization. <i>PLoS ONE</i> , 2014, 9, e98060.	1.1	5
139	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE660 Mucosal Challenge. <i>Journal of Virology</i> , 2014, 88, 9579-9589.	1.5	53
140	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	13.7	140
141	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. <i>Virology</i> , 2014, 471-473, 81-92.	1.1	21
142	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 2489-2507.	1.5	274
143	A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1. <i>Journal of Biological Chemistry</i> , 2014, 289, 29912-29926.	1.6	32
144	Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. <i>Virology</i> , 2014, 462-463, 363-376.	1.1	19

#	ARTICLE	IF	CITATIONS
145	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	5.1	47
146	Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. <i>Journal of Immunological Methods</i> , 2014, 409, 147-160.	0.6	39
147	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. <i>Journal of Immunology</i> , 2014, 192, 5802-5812.	0.4	4
148	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. <i>PLoS ONE</i> , 2014, 9, e114709.	1.1	11
149	Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2081-2094.	1.4	26
150	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. <i>Journal of Virology</i> , 2013, 87, 6986-6999.	1.5	38
151	Design of an Escherichia coli Expressed HIV-1 gp120 Fragment Immunogen That Binds to b12 and Induces Broad and Potent Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2013, 288, 9815-9825.	1.6	28
152	Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes. <i>Journal of Virology</i> , 2013, 87, 5372-5383.	1.5	59
153	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2012, 206, 431-441.	1.9	273
154	Most rhesus macaques infected with the CCR5-tropic SHIV _{AD8} generate cross-reactive antibodies that neutralize multiple HIV-1 strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19769-19774.	3.3	72
155	IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1620-1629.	1.4	67
156	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} in Rhesus Macaques: Implications for Use in Vaccine Studies. <i>Journal of Virology</i> , 2012, 86, 8516-8526.	1.5	47
157	Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 9286-9299.	1.5	24
158	Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein. <i>Journal of Virology</i> , 2001, 75, 5230-5239.	1.5	135